Nothing Special   »   [go: up one dir, main page]

MX2021015897A - Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja. - Google Patents

Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja.

Info

Publication number
MX2021015897A
MX2021015897A MX2021015897A MX2021015897A MX2021015897A MX 2021015897 A MX2021015897 A MX 2021015897A MX 2021015897 A MX2021015897 A MX 2021015897A MX 2021015897 A MX2021015897 A MX 2021015897A MX 2021015897 A MX2021015897 A MX 2021015897A
Authority
MX
Mexico
Prior art keywords
bone mineral
mineral density
low bone
factor viii
recombinant factor
Prior art date
Application number
MX2021015897A
Other languages
English (en)
Inventor
Joe Salas
Susu Duan
Katalin Kis-Toth
Gaurav Manohar Rajani
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of MX2021015897A publication Critical patent/MX2021015897A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/10Washing or bathing preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se divulgan en el presente documento métodos de tratamiento de sujetos con hemofilia y densidad mineral ósea baja (DMO), con una proteína quimérica que comprende un factor de coagulación y un dominio Fc. En ciertas modalidades, la proteína quimérica es rFVIIIFc. En ciertas modalidades, el sujeto a tratar tiene hemofilia A.
MX2021015897A 2019-06-19 2020-06-18 Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja. MX2021015897A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863831P 2019-06-19 2019-06-19
US202062968785P 2020-01-31 2020-01-31
PCT/US2020/038444 WO2020257462A1 (en) 2019-06-19 2020-06-18 Recombinant factor viii-fc for treating hemophilia and low bone mineral density

Publications (1)

Publication Number Publication Date
MX2021015897A true MX2021015897A (es) 2022-04-18

Family

ID=71465486

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015897A MX2021015897A (es) 2019-06-19 2020-06-18 Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja.

Country Status (13)

Country Link
US (1) US20220233650A1 (es)
EP (1) EP3986444A1 (es)
JP (1) JP2022537200A (es)
KR (1) KR20220024628A (es)
CN (1) CN114007637A (es)
AU (1) AU2020298233A1 (es)
BR (1) BR112021025426A2 (es)
CA (1) CA3144630A1 (es)
CO (1) CO2021016718A2 (es)
IL (1) IL289086A (es)
MX (1) MX2021015897A (es)
TW (1) TW202115127A (es)
WO (1) WO2020257462A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309309A (en) * 2021-06-23 2024-02-01 Bioverativ Therapeutics Inc Formulations of factor VIII chimeric proteins and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341174C (en) 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
EP3513804B1 (en) 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
CN104254614A (zh) 2012-01-12 2014-12-31 比奥根艾迪克Ma公司 降低经受因子viii疗法的个体中针对因子viii的免疫原性的方法
KR102097263B1 (ko) 2012-02-15 2020-04-06 바이오버라티브 테라퓨틱스 인크. Viii 인자 조성물 및 이를 제조하고 사용하는 방법
SI2882450T1 (sl) * 2012-07-11 2020-02-28 Bioverativ Therapeutics Inc. Kompleks faktorja VIII z XTEN in s proteinom von Willebrandovega faktorja in njegove uporabe
US9623088B2 (en) 2013-03-15 2017-04-18 Bioverativ Therapeutics Inc. Factor VIII polypeptide formulations
PL4176894T3 (pl) 2014-01-10 2024-07-22 Bioverativ Therapeutics Inc. Białka chimeryczne czynnika VIII i ich zastosowania
DK3137506T5 (da) * 2014-05-02 2024-10-14 Momenta Pharmaceuticals Inc Sammensætninger og fremgangsmåder relateret til genmanipulerede fc-konstrukter

Also Published As

Publication number Publication date
AU2020298233A1 (en) 2022-01-20
CA3144630A1 (en) 2020-12-24
WO2020257462A1 (en) 2020-12-24
IL289086A (en) 2022-02-01
EP3986444A1 (en) 2022-04-27
KR20220024628A (ko) 2022-03-03
WO2020257462A9 (en) 2021-02-18
TW202115127A (zh) 2021-04-16
CO2021016718A2 (es) 2022-01-17
BR112021025426A2 (pt) 2022-06-21
JP2022537200A (ja) 2022-08-24
CN114007637A (zh) 2022-02-01
US20220233650A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
PH12019502661A1 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
GB2535937A (en) Methods and compositions for modulating the immune system with Arginase I
WO2018068008A8 (en) T cells expressing membrane-anchored il-12 for the treatment of cancer
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
EA201692200A1 (ru) Комбинация леналидомида и полипептидной конструкции и ее применение
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
MY193211A (en) Gla domains as targeting agents
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
MX2022009100A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.
MX2015010404A (es) Composiciones y metodos para tratamiento y reparacion de tendones.
MX2019005693A (es) Factor viii direccionado a los globulos rojos y metodo para su uso.
MX2021015897A (es) Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.
MX2015010833A (es) Tratamiento de la enfermedad del injerto contra el huesped en pacientes de trasplante.
MX2015013092A (es) Modificación y nuevas composiciones de proteínas secretoglobinas de humano.
EA202091891A1 (ru) Ингибитор гремлина-1 для лечения перелома кости или дефекта кости
MX2019006444A (es) Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
MX2017014743A (es) Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina.
PH12021550417A1 (en) Compositions and methods for controlled ovarian stimulation
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
PH12014501044B1 (en) Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells
MX2011005651A (es) Metodos para el diagnostico y tratamiento de heridas y analisis con marcadores electricos para el pronostico de las heridas.